Advertisement

Supportive Care in Cancer

, Volume 26, Issue 2, pp 471–481 | Cite as

Guidance for establishing an integrative oncology service in the Australian healthcare setting—a discussion paper

  • Suzanne J. GrantEmail author
  • Jennifer Hunter
  • Alan Bensoussan
  • Geoff P. Delaney
Original Article

Abstract

There is an obvious mismatch between the high reported rates of use of traditional and complementary medicines (T&CM) by Australian cancer patients and cancer survivors and the low numbers of Australian cancer services integrating T&CM. An estimated 65% of Australian cancer patients use at least one form of T&CM. Over half use T&CM in conjunction with conventional cancer therapy. Yet, less than 20% of Australian hospital cancer care facilities provide access to T&CM. This compares to around 70% of UK cancer care facilities offering at least one T&CM therapy. Barriers to developing integrative oncology services include determining an appropriate service model and revenue structure; concerns with ethical and legal issues such as regulations and credentialing; and inadequate high-quality scientific evidence demonstrating safety and effectiveness, including concerns about the possibility of adversely affecting chemotherapy or radiotherapy treatment. This paper aims to provide general guidance and practical strategies for those seeking to develop integrative oncology services in Australian cancer care facilities.

Keywords

Integrative oncology Cancer care facilities Australian hospitals Complementary medicine Integrative medicine 

Notes

Acknowledgements

The authors would like to thank the assistance provided by the centres mentioned in this paper.

Compliance with ethical standards

The authors have full control over the data used in preparing this manuscript and agree to the journal reviewing the data if required.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Oh B, Butow P, Mullan B, Beale P, Pavlakis N, Rosenthal D et al (2010) The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific J Clin Oncol 6(4):342–349CrossRefGoogle Scholar
  2. 2.
    Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11(3):187–203Google Scholar
  3. 3.
    Parliament of Australia Senate Community Affairs References Committee (2005) The cancer journey: informing choice. Commonwealth of Australia, CanberraGoogle Scholar
  4. 4.
    Bell R (2010) A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs 14(3):365–370CrossRefPubMedGoogle Scholar
  5. 5.
    Amichai T, Grossman M, Richard M (2012) Lung cancer patients’ beliefs about complementary and alternative medicine in the promotion of their wellness. Eur J Oncol Nurs 15(5):520–527CrossRefGoogle Scholar
  6. 6.
    King T, Grant S, Taylor S, Houteas K, Barnett C, White K (2015) A CAM do approach: the attitudes, use and disclosure of the use of complementary and alternative medicine (CAM) in those with myeloma. Clin Lymphoma Myeloma and Leuk 15:e317–e3e8CrossRefGoogle Scholar
  7. 7.
    Beatty L, Koczwara B, Knott V, Wade T (2011) Why people chose to not use complementary therapies during cancer treatment: a focus group. Euro J Cancer Care 21(1):98–106CrossRefGoogle Scholar
  8. 8.
    Raszeja V, Jordens C, Kerridge I (2013) Survey of practices and polices relating to the use of complementary and alternatives medicines and therapies in New South Wales cancer services. Intern Med J 43:84–88CrossRefPubMedGoogle Scholar
  9. 9.
    Lim EJ, Dhillon HM, Oh BS, Vardy JL (2015) Have Australian cancer hospitals integrated complementary and alternative medicine and supportive care programs into clinical services? Adv Integr Med 2(2):116CrossRefGoogle Scholar
  10. 10.
    NCCAM (2001) Can alternative medicine be integrated into mainstream care. UK, LondonGoogle Scholar
  11. 11.
    Cohen MH, Hrbek A, Davis RB, Schachter SC, Kemper KJ, Boyer EW et al (2005) Emerging credentialing practices, malpractice liability policies, and guidelines governing complementary and alternative medical practices and dietary supplement recommendations: a descriptive study of 19 integrative health care centers in the United States. Arch Intern Med 165(3):289–296CrossRefPubMedGoogle Scholar
  12. 12.
    Grant S, Bensoussan A (2014) The process of care in integrative health care settings—a qualitative study of US practices. BMC Complement Altern Med 14(1):410CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    NHS (2015) Enhanced supportive care: integrating supportive care in oncology. Gateways, UK. https://www.england.nhs.uk/wp-content/uploads/2016/03/ca1-enhncd-supprtv-care-guid.pdf
  14. 14.
    Rossi E, Vita A, Baccetti S, Stefano M, Voller F, Zanobini A (2014) Complementary and alternative medicine for cancer patients: results of the EPAAC survey on integrative oncology centres in Europe. Support Care Cancer 23(6):1795–1806CrossRefPubMedGoogle Scholar
  15. 15.
    Greenlee H, DuPont-Reyes MJ, Balneaves LG, Carlson LE, Cohen MR, Deng G, et al. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for CliniciansGoogle Scholar
  16. 16.
    Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120PubMedGoogle Scholar
  17. 17.
    Seely DM, Weeks LC, Young S (2012) A systematic review of integrative oncology programs. Curr Oncol 19(6):e436–e461CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Furzer BJ, Petterson AS, Wright KE, Wallman KE, Ackland TR, Joske DJ (2014) Positive patient experiences in an Australian integrative oncology centre. BMC Complement Altern Med 14:158CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Furzer BJ, Wright KE, Petterson AS, Wallman KE, Ackland TR, Joske DJ (2013) Characteristics and quality of life of patients presenting to cancer support centres: patient rated outcomes and use of complementary therapies. BMC Complement Altern Med 13(1):169CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Olver I, Robotin M (2012) Perspectives on complementary and alternative medicines. Imperial College Press, LondonGoogle Scholar
  21. 21.
    CATAG (2013) Rethinking medicines decision-making in Australian hospitals: guiding principles for the quality use of off-label medicines. Council of Australian Therapeutic Advisory Groups, AustraliaGoogle Scholar
  22. 22.
    Braun L, Harris J, Katris P, Cain M, Dhillon H, Koczwara B et al (2014) Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia-Pacific J Clin Oncol 10(4):289–296CrossRefGoogle Scholar
  23. 23.
    Scott C (2012) The Dr Dorothea Sandars and Irene Lee Churchill Fellowship to study the integration of complementary and supportive therapies with conventional medical care for people with cancer—USA, UKGoogle Scholar
  24. 24.
    Kerridge IH, McPhee JR (2004) Ethical and legal issues at the interface of complementary and conventional medicine. Med J Aust 181(3):164–166PubMedGoogle Scholar
  25. 25.
    Weir M (2011) Law and ethics in complementary medicine: a handbook for practitioners in Australia and New Zealand. Allen and Unwin, AustraliaGoogle Scholar
  26. 26.
    Robotin MC, Penman AG (2006) Integrating complementary therapies into mainstream cancer care: which way forward? Med J Aust 185(7):377–379PubMedGoogle Scholar
  27. 27.
    Hunter J, Corcoran K, Phelps K, Leeder S (2012) The challenges of establishing an integrative medicine primary care clinic in Sydney. Australia J Altern Complement Med 18(11):1008–1013CrossRefPubMedGoogle Scholar
  28. 28.
    Hunter J, Corcoran K, Phelps K, Leeder S (2012) The integrative medicine team—is biomedical dominance inevitable? J Altern Complement Med 18(12):1127–1132CrossRefPubMedGoogle Scholar
  29. 29.
    Bodeker G (2012) Integrative oncology meets immunotherapy: new prospects for combination therapy grounded in Eastern medical knowledge. Chin J Integr Med 18(9):652–662CrossRefPubMedGoogle Scholar
  30. 30.
    Donabedian A (1992) Quality assurance. Structure, process and outcome. Nurs Stand 7(11 Suppl QA):4–5PubMedGoogle Scholar
  31. 31.
    Rademakers J, Delnoij D, de Boer D (2011) Structure, process or outcome: which contributes most to patients’ overall assessment of healthcare quality? BMJ Quality Safety 20(4):326–331CrossRefPubMedGoogle Scholar
  32. 32.
    Mittring N, Perard M, Witt CM (2013) Corporate culture assessments in integrative oncology: a qualitative case study of two integrative oncology centers. Evid Based Complement Alternat Med 2013:8CrossRefGoogle Scholar
  33. 33.
    Cassileth BR, Deng GE, Gomez JE, Johnstone PA, Kumar N, Vickers AJ (2007) Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):340s–354sCrossRefPubMedGoogle Scholar
  34. 34.
    WHO (2003) WHO guidelines. World Health Organisation, GenevaGoogle Scholar
  35. 35.
    Kastner M, Tricco A, Soobiah C, Lillie E, Perrier L, Horsley T et al (2012) What is the most appropriate knowledge synthesis method to conduct a review? Protocol for a scoping review. BMC Med Res Methodol 12:114CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    MacKenzie-Cook PD (2006) Challenging the new orthodoxy in integrative medicine. J Altern Complement Med 12(7):679–683CrossRefPubMedGoogle Scholar
  37. 37.
    Wardle J, Weir M, Marshall B, Archer E (2014) Regulatory and legislative protections for consumers in complementary medicine: lessons from Australian policy and legal developments. Eur J Integr Med 6(4):423–433CrossRefGoogle Scholar
  38. 38.
    Herman PM, Poindexter BL, Witt CM, Eisenberg DM (2012) Are complementary therapies and integrative care cost-effective? A systematic review of economic evaluations. BMJ Open 2(5).  https://doi.org/10.1136/bmjopen-2012-001046
  39. 39.
    Kligler B, Homel P, Harrison LB, Levenson HD, Kenney JB, Merrell W (2011) Cost savings in inpatient oncology through an integrative medicine approach. Am J Manag Care 17(12):779–784PubMedGoogle Scholar
  40. 40.
    Johnson JR, Crespin DJ, Griffin KH, Finch MD, Dusek JA (2014) Effects of integrative medicine on pain and anxiety among oncology inpatients. J Natl Cancer Inst Monogr 50(330):e337Google Scholar
  41. 41.
    Robotin M, Holliday C, Bensoussan A (2012) Defining research priorities in complementary medicine in oncology. Complement Ther Med 20(5):345–352CrossRefPubMedGoogle Scholar
  42. 42.
    Sagar SM (2008) How do we evaluate outcome in an integrative oncology program? Curr Oncol (Toronto, Ont) 15(Suppl 2):s78–s82Google Scholar
  43. 43.
    Vohra S, Cvijovic K, Boon H, Foster BC, Jaeger W, LeGatt D et al (2012) Study of Natural Health Product Adverse Reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PLoS One 7(9):e45196CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Haroon M, Ranmal R, McElroy H, Dudley J (2015) Developing clinical guidelines: how much rigour is required? Arch Dis Child Educ Pract Ed 100(2):89–96Google Scholar
  45. 45.
    Frenkel M, Cohen L, Peterson N, Palmer J, Swint K, Bruera E (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283CrossRefPubMedGoogle Scholar
  46. 46.
    Hunter J, Corcoran K, Leeder S, Phelps K (2013) Integrative medicine outcomes: what should we measure? Complement Ther Clin Pract 19(1):20–26CrossRefPubMedGoogle Scholar
  47. 47.
    Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565Google Scholar
  48. 48.
    Grant SJ, Frawley J, Bensoussan A (2015) Process of care in outpatient integrative healthcare facilities: a systematic review of clinical trials. BMC Health Serv Res 15(1):1CrossRefGoogle Scholar
  49. 49.
    Witt CM, Ausserer O, Baier S, Heidegger H, Icke K, Mayr O et al (2015) Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial. Breast Cancer Res Treat 149(2):449–460CrossRefPubMedGoogle Scholar
  50. 50.
    Coulter ID, Herman PM, Nataraj S (2013) Economic analysis of complementary, alternative, and integrative medicine: considerations raised by an expert panel. BMC Complement Altern Med 13(1):1–9CrossRefGoogle Scholar
  51. 51.
    Deng G, Weber W, Sood A, Kemper KJ (2010) Research on integrative healthcare: context and priorities. EXPLORE: J Sci Healing 6(3):143–158CrossRefGoogle Scholar
  52. 52.
    Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai J-S et al (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25(32):5106–5112CrossRefPubMedGoogle Scholar
  53. 53.
    Hibbard JH, Stockard J, Mahoney ER, Tusler M (2004) Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 39(4 Pt 1):1005–1026CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Hibbard JH, Greene J, Overton V (2013) Patients with lower activation associated with higher costs; delivery systems should know their patients’ scores. Health Aff 32(2):216–222CrossRefGoogle Scholar
  55. 55.
    Polley M, Frenkel M, Balneaves L, Zollman C, Seely D, Abrams D, et al. Developing guidelines for the collection of patient outcomes data in clinical integrative oncology settings. Abstract 60. Presented November 15, 2015. SIO 12th International Conference; 15 November; Boston, USA2015Google Scholar
  56. 56.
    Girgs A, Delaney G, Miller A (2015) Utilising eHealth to support survivorship care. Cancer Forum 39(2):86–89Google Scholar
  57. 57.
    Lim E, Vardy JL, Oh B, Dhillon HM (2017) Integration of complementary and alternative medicine into cancer-specific supportive care programs in Australia: a scoping study. Asia Pac J Clin Oncol 13(1):6–12Google Scholar
  58. 58.
    Grant SJ, Bensoussan A (2014) The process of care in integrative health care settings—a qualitative study of US practices. BMC Complement Altern Med 14(1):1CrossRefGoogle Scholar
  59. 59.
    Hunter J, Leeder S (2013) Patient questionnaires for use in the integrative medicine primary care setting—a systematic literature review. Eur J Integr Med 5(3):194–216CrossRefGoogle Scholar
  60. 60.
    Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88(9):2164–2171CrossRefPubMedGoogle Scholar
  61. 61.
    Jolliffe R, Seers H, Jackson S, Caro E, Weeks L, Polley MJ (2015) The responsiveness, content validity, and convergent validity of the Measure Yourself Concerns and Wellbeing (MYCaW) patient-reported outcome measure. Integr Cancer Ther 14(1):26–34CrossRefPubMedGoogle Scholar
  62. 62.
    Cella D, Choi S, Garcia S, Cook KF, Rosenbloom S, Lai J-S et al (2014) Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. Qual Life Res 23(10):2651–2661CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Suzanne J. Grant
    • 1
    • 2
    Email author
  • Jennifer Hunter
    • 2
  • Alan Bensoussan
    • 2
  • Geoff P. Delaney
    • 3
  1. 1.Chris O’Brien LifehouseCamperdownAustralia
  2. 2.National Institute of Complementary MedicineWestern Sydney UniversityPenrithAustralia
  3. 3.Cancer Services, South Western Sydney Local Health District, Cancer Therapy CentreLiverpool HospitalLiverpoolAustralia

Personalised recommendations